AstraZeneca prevails in GSK royalties row at UK High Court

06-04-2023

Muireann Bolger

AstraZeneca prevails in GSK royalties row at UK High Court

Mats Wiklund / Shutterstock.com

Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.


AstraZeneca, royalties, dispute, High Court, GSK, Tesaro, Zejula, rights, licensing agreement, PARP inhibitors, Justice David Richards, cancer treatment

LSIPR